Danny V Colombara1,2,3, Lisa E Manhart4, Joseph J Carter5, Stephen E Hawes4, Noel S Weiss4,5, James P Hughes6, Matt J Barnett5, Gary E Goodman5, Jennifer S Smith7, You-Lin Qiao8, Denise A Galloway5. 1. Institute for Health Metrics and Evaluation, University of Washington, 2301 Fifth Ave., Suite 600, Seattle, WA, 98121, USA. dvc2@uw.edu. 2. Department of Epidemiology, School of Public Health, University of Washington, 1959 NE Pacific Street, Health Sciences Building F-250, Box 357236, Seattle, WA, 98195-7236, USA. dvc2@uw.edu. 3. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA, 98109-1024, USA. dvc2@uw.edu. 4. Department of Epidemiology, School of Public Health, University of Washington, 1959 NE Pacific Street, Health Sciences Building F-250, Box 357236, Seattle, WA, 98195-7236, USA. 5. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA, 98109-1024, USA. 6. Department of Biostatistics, School of Public Health, University of Washington, F-600, Health Sciences Building, Box 357232, Seattle, WA, 98195-7232, USA. 7. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, CB #7435, Chapel Hill, NC, 27599-7435, USA. 8. Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, 17 South Pan Jia Yuan Lane, Chaoyang Dist., P. O. Box 2258, Beijing, 100021, People's Republic of China.
Abstract
PURPOSE: To test whether infection with select human polyomaviruses (HPyV) and human papillomaviruses (HPV) is associated with incident lung cancer. METHODS: We performed a nested case-control study, testing serum from the carotene and retinol efficacy trial, conducted 1985-2005, for antibodies to Merkel cell (MCV), KI (KIV), and WU (WUV) HPyVs as well as to six high-risk and two low-risk HPV types. Incident lung cancer cases (n = 200) were frequency-matched with controls (n = 200) on age, enrollment and blood draw dates, intervention arm assignment, and the number of serum freeze/thaw cycles. Sera were tested using multiplex liquid bead microarray antibody assays. We used logistic regression to assess the association between HPyV and HPV antibodies and lung cancer. RESULTS: There was no evidence of a positive association between levels of MCV, KIV, or WUV antibodies and incident lung cancer (p corrected >0.10 for all trend tests; odds ratio (OR) range 0.72-1.09, p corrected >0.10 for all). There was also no evidence for a positive association between HPV 16 or 18 infection and incident lung cancer (p corrected ≥0.10 for all trend tests; OR range 0.25-2.54, p > 0.05 for all OR > 1), but the number of persons with serologic evidence of these infections was small. CONCLUSIONS: Prior infection with any of several types of HPyV or HPV was not associated with subsequent diagnosis of lung cancer. Infection with these viruses likely does not influence a person's risk of lung cancer in Western smoking populations.
RCT Entities:
PURPOSE: To test whether infection with select humanpolyomaviruses (HPyV) and human papillomaviruses (HPV) is associated with incident lung cancer. METHODS: We performed a nested case-control study, testing serum from the carotene and retinol efficacy trial, conducted 1985-2005, for antibodies to Merkel cell (MCV), KI (KIV), and WU (WUV) HPyVs as well as to six high-risk and two low-risk HPV types. Incident lung cancer cases (n = 200) were frequency-matched with controls (n = 200) on age, enrollment and blood draw dates, intervention arm assignment, and the number of serum freeze/thaw cycles. Sera were tested using multiplex liquid bead microarray antibody assays. We used logistic regression to assess the association between HPyV and HPV antibodies and lung cancer. RESULTS: There was no evidence of a positive association between levels of MCV, KIV, or WUV antibodies and incident lung cancer (p corrected >0.10 for all trend tests; odds ratio (OR) range 0.72-1.09, p corrected >0.10 for all). There was also no evidence for a positive association between HPV 16 or 18 infection and incident lung cancer (p corrected ≥0.10 for all trend tests; OR range 0.25-2.54, p > 0.05 for all OR > 1), but the number of persons with serologic evidence of these infections was small. CONCLUSIONS:Prior infection with any of several types of HPyV or HPV was not associated with subsequent diagnosis of lung cancer. Infection with these viruses likely does not influence a person's risk of lung cancer in Western smoking populations.
Authors: Gary E Goodman; Mark D Thornquist; John Balmes; Mark R Cullen; Frank L Meyskens; Gilbert S Omenn; Barbara Valanis; James H Williams Journal: J Natl Cancer Inst Date: 2004-12-01 Impact factor: 13.506
Authors: Muhammed Babakir-Mina; Massimo Ciccozzi; Alessandra Lo Presti; Francesco Greco; Carlo Federico Perno; Marco Ciotti Journal: J Med Virol Date: 2010-03 Impact factor: 2.327
Authors: Erica A Siebrasse; Alejandro Reyes; Efrem S Lim; Guoyan Zhao; Rajhab S Mkakosya; Mark J Manary; Jeffrey I Gordon; David Wang Journal: J Virol Date: 2012-06-27 Impact factor: 5.103
Authors: Muhammed Babakir-Mina; Massimo Ciccozzi; Laura Campitelli; Stefano Aquaro; Achille Lo Coco; Carlo Federico Perno; Marco Ciotti Journal: J Med Virol Date: 2009-03 Impact factor: 2.327
Authors: Danny V Colombara; Lisa E Manhart; Joseph J Carter; Stephen E Hawes; Noel S Weiss; James P Hughes; You-Lin Qiao; Philip R Taylor; Jennifer S Smith; Denise A Galloway Journal: BMC Cancer Date: 2016-06-01 Impact factor: 4.430